^
    Back
    Association details:
    Biomarker:RET fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:everolimus (mTOR inhibitor) +
    Caprelsa (vandetanib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.

    Published date:
    05/16/2018
    Excerpt:
    V+E has significant activity in RET+ NSCLC identified by NGS, with an ORR of 70% and a median PFS of 8 months.
    DOI:
    10.1200/JCO.2018.36.15_suppl.9035
    Trial ID:
    NCT01582191